Medicine & Science in Sports & Exercise:
Influence of Diet, Exercise, and Serum Vitamin D on Sarcopenia in Postmenopausal Women
MASON, CAITLIN1; XIAO, LIREN1; IMAYAMA, IKUYO1; DUGGAN, CATHERINE R.1; FOSTER-SCHUBERT, KAREN E.2; KONG, ANGELA3; CAMPBELL, KRISTIN L.4; WANG, CHING-YUN1,2; VILLASENOR, ADRIANA1; NEUHOUSER, MARIAN L.1,2; ALFANO, CATHERINE M.5; BLACKBURN, GEORGE L.6; MCTIERNAN, ANNE1,2
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2University of Washington, Seattle, WA; 3University of Illinois at Chicago, Chicago, IL; 4University of British Columbia, Vancouver, BC; 5Office of Cancer Survivorship, National Cancer Institute, Bethesda, MD; and 6Division of Nutrition, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA
Address for correspondence: Anne McTiernan, M.D., Ph.D., Prevention Center, Fred Hutchinson Cancer Research Center, M4-B874, PO Box 19024, Seattle, WA 98109; E-mail: firstname.lastname@example.org.
Submitted for publication April 2012.
Accepted for publication October 2012.
Purpose: The objective of this study is to investigate the effects of 12 months of dietary weight loss and/or aerobic exercise on lean mass and the measurements defining sarcopenia in postmenopausal women and to examine the potential moderating effect of serum 25-hydroxyvitamin D (25(OH)D) and age.
Methods: Four hundred thirty-nine overweight and obese postmenopausal women were randomized to diet modification (N = 118), exercise (N = 117), diet + exercise (N = 117), or control (N = 87). The diet intervention was a group-based program with a 10% weight loss goal. The exercise intervention was 45 min·d−1, 5 d·wk−1, of moderate-to-vigorous intensity aerobic activity. Total and appendicular lean mass (ALM) were quantified by dual x-ray absorptiometry at baseline and 12 months. A skeletal muscle index (SMI = ALM (kg) / height (m2)) and the prevalence of sarcopenia (SMI <5.67 kg·m−2) were calculated. Serum 25(OH)D was assayed using a competitive chemiluminescent immunoassay.
Results: Dietary weight loss resulted in a significant decrease in lean mass and a borderline significant decrease in ALM and SMI compared with controls. In contrast, aerobic exercise significantly preserved ALM and SMI. Diet + exercise attenuated the loss of ALM and SMI compared with diet alone and did not result in significant loss of total mass or ALM compared with controls. Neither serum 25(OH)D nor age was significant moderators of the intervention effects.
Conclusions: Aerobic exercise added to dietary weight loss can attenuate the loss of ALM during weight loss and may be effective for the prevention and treatment of sarcopenia among overweight and obese postmenopausal women.
Weight gain leading to overweight and obesity is associated with a proportional increase in lean tissue. However, excess weight is not necessarily protective against the age-related decline in muscle mass known as sarcopenia (31). As such, the term sarcopenic obesity has been coined to describe the simultaneous presence of both obesity and low muscle mass, which confers a higher risk of functional impairment and physical disability than sarcopenia alone (30).
Although weight loss among obese individuals is recommended for chronic disease prevention (25), the prudence of weight loss among overweight and obese older adults has been debated over concerns about the potentially deleterious concurrent loss of muscle and bone mass (8,19,27,40). The relative loss of lean mass compared with fat mass represents a significantly greater percentage of weight loss in older compared with younger adults (27). Thus, accelerated muscle loss with weight loss is a particularly justified concern in older persons with a body phenotype of sarcopenic obesity. Whether, and how, weight loss can be achieved in persons with or at risk of sarcopenia without the detrimental loss of lean mass is uncertain.
Difficulty remains in identifying sarcopenia in research and clinical settings given that no formal, universally accepted definition yet exists. Baumgartner et al. (2) were the first to use a dichotomous method whereby sarcopenia was defined as height-adjusted appendicular muscle mass (muscle mass/height2) two SD or more below the mean of a young reference population, as measured by dual x-ray absorptiometry (DXA). Several other approaches have used similar types of cut-points but have relied on other measurement tools such as bioelectrical impedance and computed tomography (13), have adjusted for total weight rather than height (16), or used residuals from linear regression models (26). Ongoing efforts are being made to establish a definition based on pathophysiology and associated risk; however, the process needed to disentangle the complex interrelationships involved makes this difficult (9,39).
Although muscle loss is a consequence of aging, considerable interindividual differences exist owing to a variety of lifestyle and other factors. Serum 25-hydroxyvitamin D (25(OH)D), the most common indicator of whole-body vitamin D status, is positively associated with lean mass, physical performance, and muscle strength (11,15,17), whereas intervention studies have demonstrated improvements in physical functioning and reduced risk of falls in older adults after vitamin D supplementation (7). Vitamin D receptors are present in human skeletal muscle (5,35), and previous studies have linked vitamin D receptor polymorphisms to reduced muscle mass and function in older adults, suggesting that vitamin D does play a role in sarcopenia. Yet, there remains little consensus on the mechanisms underlying the observed associations (12). Whether vitamin D status moderates the effect of weight loss by caloric restriction or exercise on lean mass by supporting muscle preservation remains unknown.
The purpose of this study was to investigate the effects of 12 months of weight loss through caloric restriction and/or exercise interventions on lean mass and on measurements defining sarcopenia (e.g., appendicular lean mass (ALM) and skeletal muscle index (SMI)) among postmenopausal women and to investigate the potential moderating effects of serum 25(OH)D status and age. We hypothesized that women with high 25(OH)D will preserve a greater amount of lean mass than women with low 25(OH)D.
PARTICIPANTS AND METHODS
The Nutrition and Exercise in Women (NEW) study, conducted from 2005 to 2009, was a 12-month randomized controlled trial testing the effects of caloric restriction and/or exercise on circulating hormones and other outcomes. Study procedures were reviewed and approved by the Fred Hutchinson Cancer Research Center Institutional Review Board in Seattle, WA, and all participants provided informed written consent.
Participants were overweight or obese (body mass index (BMI) ≥25.0 or ≥23.0 kg·m−2 if Asian American) postmenopausal women (50–75 yr), recruited through media and mass mailings. Specific exclusion criteria included >100 min·wk−1 of moderate physical activity; diabetes, fasting blood glucose ≥126 mg·dL−1, or use of diabetes medications; postmenopausal hormones use within 3 months; history of serious medical condition(s); alcohol intake more than two drinks a day; current smoking; contraindication to the study interventions (e.g., abnormal exercise tolerance test); current or planned participation in another weight loss program; use of weight loss medications; or any additional factors that might interfere with the measurement of outcomes or intervention success (e.g., inability to attend facility-based sessions).
Randomization and interventions.
Eligible women were randomized to one of four study arms: 1) reduced-calorie dietary modification (N = 118), 2) moderate-to-vigorous intensity aerobic exercise (N = 117), 3) combined diet and exercise (N = 117), or 4) control (no intervention) (N = 87). Computerized random assignment was stratified according to BMI (≥30.0 or <30.0 kg·m−2) and participants’ self-reported race/ethnicity (White, Black, and others). To achieve a proportionally smaller number of women assigned to the control group, we used permuted blocks randomization with blocks of 4, wherein the control assignment was randomly eliminated from each block with a probability of approximately 1 in 4.
The interventions have been previously described in detail (10). Briefly, the dietary intervention was modified from the Diabetes Prevention Program (18) and Look AHEAD (Action for Health in Diabetes) (33) lifestyle behavior change programs with goals of 1200–2000 kcal·d−1, <30% daily energy intake from fat, and 10% loss of baseline weight within 6 months with weight maintenance thereafter. Participants met individually with a dietitian on at least two occasions, followed by weekly group (5–10 women) meetings for 6 months and monthly group meetings thereafter, in addition to phone or e-mail contact. The women were weighed at each visit, and both the dietitian and participant tracked this on a graph. Women were asked to keep a daily food journal for at least 6 months or until they reached their individual weight loss goal (10%). Journals were collected by the dietitian and returned with feedback after being analyzed. Journaling, weekly weight loss, and the total number of sessions attended were used as measures of adherence to the diet intervention.
The exercise intervention began with 15-min sessions at 60%–70% maximal heart rate (determined by baseline exercise treadmill testing) on 3 d·wk−1 and progressed incrementally to the target 70%–85% maximal heart rate for 45 min, 5 d·wk−1, by the 7th week after enrollment, where it was maintained for the remainder of the study. Participants attended three supervised sessions per week at the study facility and exercised 2 d·wk−1 at home. Facility-based exercise consisted of treadmill walking, stationary cycling, and use of other aerobic machines, whereas a variety of home exercises were encouraged including walking/hiking, aerobics, and bicycling. Women wore Polar heart rate monitors (Polar Electro, Lake Success, NY) during both facility and home exercise sessions to assist with attaining their target heart rate. In addition, they recorded the mode and duration of exercise, and the peak heart rate was achieved. At home, women also recorded their relative perceived exertion. Activity logs were completed by each participant and were reviewed weekly by study staff to monitor compliance and to intervene when needed. Activities of ≥4 METs (1) were counted toward the prescribed target of 225 min·wk−1 of moderate-to-vigorous aerobic exercise. A small amount of resistance training and stretching to strengthen joints and limit injury was recommended, although not required. Sixty-eight percent (n = 159) of women randomized to exercise intervention reported doing strength training an average of once per week, but duration was not recorded.
Participants randomized to diet + exercise received the diet intervention in separate sessions and were instructed not to discuss diet during supervised exercise. The control group was requested not to change their diet or exercise habits for 12 months.
Outcomes and follow-up.
All study measures were obtained and analyzed by trained personnel who were blinded to the participants’ randomization status.
Demographic information, medical history, dietary intake (via a validated 120-item self-administered food frequency questionnaire that assessed nutrient intake over the previous 6 months ), supplement use, physical activity patterns (via a modified, interview-administered Minnesota Physical Activity Questionnaire describing the previous 12 months ), and average pedometer (Accusplit, Silicon Valley, CA) daily step count for 1 wk were collected at baseline and 12 months. Cardiorespiratory fitness (V˙O2max) was assessed using a maximal graded treadmill test according to a modified branching protocol (28). Heart rate and oxygen uptake were continuously monitored with an automated metabolic cart (MedGraphics, St. Paul, MN).
Body composition assessment.
Participants wore a hospital gown without shoes for anthropometric measurements. BMI (kg·m−2) was calculated from weight and height, measured to the nearest 0.1 kg and 0.1 cm, respectively, with a balance beam scale and stadiometer. Waist circumference was measured to the nearest 0.5 cm at the minimal waist. Body composition was measured on a DXA whole-body scanner (Encore 2004 software, v. 8.80.001; GE Lunar, Madison, WI), including the total body bone-free lean mass and ALM, which was calculated as the sum of the upper and lower limb muscular masses. ALM was normalized to height by calculating an SMI (SMI = ALM (kg) / height (m2)] and used to determine the prevalence of sarcopenia as SMI ≤5.67 kg·m−2 according to current consensus recommendations (9).
Fasting venous blood samples (50 mL) were collected during clinic visits before randomization and at 12 months. Participants consumed only water for 12 h prior and did not exercise for 24 h preceding the blood draw. Blood was processed within 1 h, and samples were stored at −70°C.
Serum 25(OH)D was assayed by direct, competitive chemiluminescent immunoassay using the DiaSorin LIAISON 25-OH vitamin D total assay (Heartland Assays, Inc., Ames, IA). Samples were analyzed in batches such that each participant’s baseline and 12-month samples were assayed simultaneously, the number of samples from each intervention group was approximately equal, participant randomization dates were similar, and sample order was random. The intra- and interassay coefficients of variation were 8.2% and 11.0%, respectively.
All statistical analyses were performed using SAS software version 9.2 (SAS Institute, Cary, NC). For the main analyses, missing data were imputed by multiple imputation (PROC MI). Body composition variables were imputed based on baseline values of the variable of interest, age, race/ethnicity, and BMI. Five imputed data sets were created (32) and results were combined (PROC MIANALYZE). For all other analyses, only available data were used. Differences in baseline characteristics between groups were tested using t-tests and chi-square or Fisher exact tests for frequency comparisons as appropriate. Pearson correlation coefficients were calculated between age, 25(OH)D, body fat, lean mass, ALM, and SMI.
Mean changes in lean mass, ALM, and SMI from baseline to 12 months within each intervention group were computed and compared with controls using the generalized estimating equations modification of linear regression to account for intraindividual correlation over time. Age, race/ethnicity, baseline BMI, vitamin D intake (food + supplements), percent calories from protein, and percent weight loss were examined as covariates. Additional comparisons between the diet and exercise groups to the diet + exercise group were also performed. Adjustment for multiple comparisons was made via Bonferroni correction (two-sided alpha 0.05 / 5 = 0.01). The intervention effects were examined based on the assigned treatment at randomization, regardless of adherence or study retention (i.e., intent-to-treat). The effect of vitamin D status was investigated by repeating the main analyses after stratification according to the median split (25(OH)D ≤22 or >22 ng·mL−1) and the following serum 25(OH)D concentrations: <20 ng·mL−1, 20–30 ng·mL−1, and >30 ng·mL−1 (14). The season of randomization (March to May, June to August, September to November, and December to February) was also included as a covariate in this model. Similarly, potential differences in younger compared with older women were also compared in stratified analyses (50–60 and 60–75 yr) and tested for a significant interaction effect.
At 12 months, 397 participants underwent a DXA scan, 371 completed a treadmill test, and 39 did not complete the study. One participant was missing baseline blood measures and was excluded from this analysis. The flow of participants through the NEW trial and a comparison of baseline participant characteristics between randomized groups have been previously published (10). As reported previously (23), the mean serum 25(OH)D concentration among participants was 22.5 ng·mL−1 (range, 4.1–57.0 ng·mL−1). Serum 25(OH)D varied according to season of randomization; however, the frequency of randomization by season did not differ across groups (chi-square P = 0.29). Serum 25(OH)D was inversely correlated with percent body fat (r = −0.12, P = 0.01) and positively associated with lean mass (r = 0.11, P = 0.02) but was not significantly correlated with ALM (r = −0.09, P = 0.06) or SMI (r = −0.09, P = 0.07) at baseline.
Prevalence of sarcopenia.
Table 1 shows participant characteristics by sarcopenic status. At baseline, 76 (17.4%) participants met the criteria for sarcopenia (SMI ≤5.67). Women with sarcopenia, compared with women without sarcopenia, had a lower mean BMI (31.4 vs 28.2 kg·m−2, P < 0.0001) and waist circumference (90.2 vs 95.4 cm, P < 0.0001), less lean mass (36.0 vs 41.2 kg, P < 0.0001), and a higher mean percent body fat (48.5% vs 47.0%, P = 0.006) (Table 1). No significant differences in V˙O2max, pedometer steps per day, percent calories from fat or protein, use of vitamin D supplements, or serum 25(OH)D were detected by sarcopenic status.
At 12 months, the mean weight change was −2.4% (P = 0.03) in the exercise group, −8.5% (P < 0.001) in the diet group, and −10.8% (P < 0.001) in the diet + exercise group, compared with −0.8% among controls (10). Women randomized to exercise alone participated in moderate-to-vigorous activity for a mean of 163.3 min·wk−1, whereas women randomized to diet + exercise participated for 171.5 min·wk−1. Both groups significantly increased average pedometer steps per day (+3202 and +4038 steps per day, respectively) and V˙O2max (+0.17 and +0.12 L·min−1, respectively) compared with baseline. Daily percent calories from fat decreased in both the diet (−6.7%) and diet + exercise (−8.0%) groups. In both diet groups, women attended an average of 27 diet counseling sessions (86%).
After 12 months, lean mass decreased significantly in the diet group compared with controls (−1.1 kg vs −0.1 kg, P < 0.001), with a borderline significant decrease in ALM and SMI (P = 0.02 and P = 0.01, respectively) (Table 2). In contrast, aerobic exercise significantly preserved ALM (P = 0.003) and SMI (P = 0.004) compared with controls, despite no change in total lean mass. No significant changes in lean mass (P = 0.20), ALM (P = 0.90), or SMI (P = 0.68) were detected between the diet + exercise group and controls after 12 months. Compared with the diet alone group, the reductions in ALM and SMI were smaller in the diet + exercise group (P < 0.01). None of the results were meaningfully changed after further adjustment for total percent weight loss or for percent body fat loss rather than BMI.
Among women who met the criteria for sarcopenia at baseline, three cases (14%) in the control group, one case (8%) in the diet group, eight cases (50%) in the exercise group, and six cases (35%) in the diet + exercise group no longer met the criteria for sarcopenia by 12 months. Conversely, the incidence rates of sarcopenia among women who did not meet the criteria at baseline were 10% (n = 6) in the control group, 12% (n = 11) in the diet alone group, 7% (n = 6) in the exercise group, and 9% (n = 8) in the diet + exercise group (Table 3). Although both the exercise and exercise + diet interventions were associated with a lower risk of incident sarcopenia compared with controls, the relative risk estimates were not statistically significant after adjustment for age, ethnicity, and percent weight loss.
Baseline vitamin D status did not significantly affect the loss of lean mass, ALM, or SMI in any intervention group (Table 4), and no significant interaction effect was detected when serum 25(OH)D was stratified and tested using a median split (25(OH)D ≤22 or >22 ng·mL−1) (results not shown). No significant interaction effects were observed according to age (<60 or ≥60 yr) (Table 5).
Given the increased risk of disability, frailty, and fracture risk associated with sarcopenia (10–12), the potential loss of lean mass can be a deterrent to prescribed weight loss for overweight and obese older adults. Yet, behavioral lifestyle changes leading to modest weight loss of 5%–10% are generally sufficient to yield significant improvements in a variety of chronic disease risk factors (14). Thus, the effects of different lifestyle interventions for obesity treatment on lean mass in older populations are of particular clinical importance.
In this study of overweight and obese postmenopausal women, 12 months of aerobic exercise resulted in a small but significant increase in ALM and SMI compared with a net loss among controls. In contrast, 12 months of dietary weight loss (without exercise) resulted in a significant loss of lean mass and a borderline significant decrease in ALM and SMI compared with controls. The combination of dietary weight loss + exercise attenuated the loss of ALM and SMI compared with diet alone and did not result in the significant loss of total lean mass or ALM compared with controls while still achieving significant and meaningful weight loss and accompanying metabolic improvements (10,22). Although resistance exercise is typically considered the best approach for preserving muscle mass with aging, its utility for promoting weight loss, especially in older women, is not known. Our data suggest that aerobic exercise has some benefit for maintaining lean body mass when combined with dietary weight loss. Future studies should investigate whether the addition of resistance training, and at what dose, may confer additional benefits for the preservation of muscle mass and function, as well as bone during weight loss.
Although serum 25(OH)D was positively associated with lean mass at baseline, vitamin D status did not appear to significantly influence the loss of total lean mass or ALM in any intervention group. In the control group, diet group, and diet + exercise group, women with serum 25(OH)D >30 ng·mL−1 lost quantitatively less lean mass than those with lower baseline values; however, the groups may have been too small to detect a significant relationship. Vitamin D receptors are present in human skeletal muscle (5,35), and serum 25(OH)D concentrations have been positively associated with physical performance and overall physical fitness in cross-sectional studies of older women (11,37). Furthermore, vitamin D3 supplementation has been shown to increase muscle strength in older adults with low vitamin D (20,24); however, the mechanisms underlying the effect of vitamin D on muscle strength are not fully understood.
The prevalence of sarcopenia increases with advancing age, as does the rate of muscle loss (41). We observed a greater loss of lean mass for 12 months in older women, regardless of intervention assignment; however, the intervention effects on lean mass did not differ according to age, suggesting that aerobic exercise is equally effective in preventing the loss of lean mass in older compared with middle-aged women. Additional studies will be required to determine whether similar effects are seen in women older than 75 yr.
For the purpose of this study, we opted to use the DXA-based approach first described by Baumgartner et al. (2), with the SMI cut-off suggested in a more recent international consensus definition of sarcopenia (9). The use of DXA for precise assessment of total and regional lean mass is a study strength. Additional strengths include the relatively large size and adequate statistical power to examine differences in lean mass in women assigned to diet versus exercise versus both combined, as well as excellent intervention adherence and study retention. A limitation is that we did not measure muscle function. A growing body of related research suggests that muscle function, independent of muscle size, is an important determinant of physical functioning and risk of disability (36). Several groups including the European Working Group on Sarcopenia in Older People (6) and the International Sarcopenia Consensus Conference Working Group (9) have recently recommended using the presence of both low muscle mass and low muscle function (strength or performance) to identify sarcopenia. Future studies should examine the effects of weight loss and various exercise regimens on this aspect of sarcopenia, as well as the extent to which changes in muscle mass are associated with functional outcomes.
The etiology of sarcopenia is complex with multiple contributing factors over the lifespan, including early life developmental influences, diet, physical inactivity, chronic disease, specific drug treatments, and the aging process (21,34). Several mechanisms have been implicated in the onset and progression of sarcopenia, including endocrine factors such as insulin resistance, inflammation, changes in sex hormones, disuse, motor neuron loss, inadequate nutrition or nutrient malabsorption, and cachexia (4,21). Exercise may directly and indirectly influence the sarcopenic process through several of these mechanisms. Further research is needed to disentangle the complex and interrelated pathways influencing the development of sarcopenia and to establish better exercise prescriptions to minimize its negative consequences.
This study demonstrates that regular aerobic exercise is effective for the prevention and management of muscle loss among postmenopausal women undergoing weight loss, and that aerobic exercise added to a dietary weight loss program should be considered as a viable strategy to mitigate the potentially adverse effects of weight loss among older overweight and obese women. These observations are particularly important given that the loss of lean mass experienced during weight loss is not fully recovered with weight regain (3). The potential for a disproportionate regain in fat mass among older adults means that unsuccessful weight loss maintenance could further increase the risks associated with sarcopenic obesity and underscores the importance of incorporating regular exercise into weight loss programs for older adults. Higher serum 25(OH)D levels do not appear to protect against the loss of lean mass during weight loss in this population.
This study was funded through NIH R01 CA102504 and U54-CA116847. CM and KLC were supported by fellowships from the Canadian Institutes of Health Research (CIHR).
KFS received support from NIH 5KL2RR025015-03.
AK was supported by NCI R25 CA094880 and is now supported by NCI 2R25CA057699-16.
While working on the trial, CMA was employed at the Ohio State University and affiliated with NCI after completion of her effort on the NEW trial.
Trial Registration: www.clinicaltrials.gov Identifier NCT00470119.
There are no conflicts of interest reported with any authors of this article.
The results of this study do not constitute endorsement by the American College of Sports Medicine.
1. Ainsworth BE, Haskell WL, Whitt MC, et al.. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc
. 2000; 32 (9 Suppl): S498–506.
2. Baumgartner RN, Koehler KM, Gallagher D, et al.. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol
. [Comparative Study Research Support, U.S. Government, P.H.S.]. 1998; 147 (8): 755–63.
3. Beavers KM, Lyles MF, Davis CC, Wang X, Beavers DP, Nicklas BJ. Is lost lean mass from intentional weight loss recovered during weight regain in postmenopausal women? Am J Clin Nutr
. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. 2011; 94 (3): 767–74.
4. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care
. 2012; 15 (1): 12–22.
5. Bischoff HA, Borchers M, Gudat F, et al.. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J
. 2001; 33 (1): 19–24.
6. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al.. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing
. [Consensus Development Conference Practice Guideline Research Support, Non-U.S. Government]. 2010; 39 (4): 412–23.
7. Dawson-Hughes B. Serum 25-hydroxyvitamin D and functional outcomes in the elderly. Am J Clin Nutr
. [Research Support, U.S. Government, Non-P.H.S. Review]. 2008; 88 (2): 537S–40.
8. Ensrud KE, Ewing SK, Stone KL, Cauley JA, Bowman PJ, Cummings SR. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. J Am Geriatr Soc
. 2003; 51 (12): 1740–7.
9. Fielding RA, Vellas B, Evans WJ, et al.. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc
. [Research Support, Non-U.S. Government]. 2011; 12 (4): 249–56.
10. Foster-Schubert KE, Alfano CM, Duggan C, et al.. Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese postmenopausal women. Obesity
. 2012; 12 (8): 1628–38.
11. Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos Int
. 2005; 16 (11): 1425–31.
12. Gilsanz V, Kremer A, Mo AO, Wren TA, Kremer R. Vitamin D status and its relation to muscle mass and muscle fat in young women. J Clin Endocrinol Metab
. 2010; 95 (4): 1595–601.
13. Goodpaster BH, Park SW, Harris TB, et al.. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci
. [Research Support, N.I.H., Intramural]. 2006; 61 (10): 1059–64.
14. Holick MF. Vitamin D deficiency. New Engl J Med
. 2007; 357 (3): 266–81.
15. Houston DK, Cesari M, Ferrucci L, et al.. Association between vitamin D status and physical performance: the InCHIANTI study. J Gerontol A Biol Sci Med Sci
. 2007; 62 (4): 440–6.
16. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc
. [Research Support, Non-U.S. Government Research Support, U.S. Government, P.H.S.]. 2002; 50 (5): 889–96.
17. Kim MK, Baek KH, Song KH, et al.. Vitamin D deficiency is associated with sarcopenia in older Koreans, regardless of obesity: the Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV) 2009. J Clin Endocrinol Metab
. [Research Support, Non-U.S. Government]. 2011; 96 (10): 3250–6.
18. Knowler WC, Barrett-Connor E, Fowler SE, et al.. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med
. 2002; 346 (6): 393–403.
19. Langlois JA, Mussolino ME, Visser M, Looker AC, Harris T, Madans J. Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study. Osteoporos Int
. 2001; 12 (9): 763–8.
20. Lips P, Binkley N, Pfeifer M, et al.. Once-weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency. Am J Clin Nutr
. 2010; 91 (4): 985–91.
21. Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L. Sarcopenia in the elderly: diagnosis, physiopathology and treatment. Maturitas
. 2012; 71 (2): 109–14.
22. Mason C, Foster-Schubert KE, Imayama I, et al.. Dietary weight loss and exercise effects on insulin resistance in postmenopausal women. Am J Prev Med
. [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Government]. 2011; 41 (4): 366–75.
23. Mason C, Xiao L, Imayama I, et al.. Effects of weight loss on serum vitamin D in postmenopausal women. Am J Clin Nutr
. 2011; 94 (1): 95–103.
24. Moreira-Pfrimer LD, Pedrosa MA, Teixeira L, Lazaretti-Castro M. Treatment of vitamin D deficiency increases lower limb muscle strength in institutionalized older people independently of regular physical activity: a randomized double-blind controlled trial. Ann Nutr Metab
. 2009; 54 (4): 291–300.
25. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. Obes Res
. 1998; 6 (Suppl 2): S51–209.
26. Newman AB, Kupelian V, Visser M, et al.. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc
. [Comparative Study Research Support, U.S. Government, P.H.S.]. 2003; 51 (11): 1602–9.
27. Newman AB, Lee JS, Visser M, et al.. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr
. 2005; 82 (4): 872–8; quiz 915–6.
28. Pate R, Blair S, Durstine J. Guidelines for Exercise Testing and Prescription
. Philadelphia (PA).: Lea & Febinger; 1991. pp. 70–2.
29. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women’s Health Initiative food frequency questionnaire. Ann Epidemiol
. 1999; 9 (3): 178–87.
30. Rolland Y, Lauwers-Cances V, Cristini C, et al.. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l’OSteoporose) Study. Am J Clin Nutr
. [Research Support, Non-U.S. Government]. 2009; 89 (6): 1895–900.
31. Rosenberg IR. Summary comments. Am J Clin Nutr
. 1989; 50: 1231–3.
32. Rubin DB, Schenker N. Multiple imputation for interval estimation from simple random samples with ignorable nonresponse. J Am Stat Assoc
. 1986; 81 (394): 366–74.
33. Ryan DH, Espeland MA, Foster GD, et al.. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials
. 2003; 24 (5): 610–28.
34. Sayer AA, Syddall H, Martin H, Patel H, Baylis D, Cooper C. The developmental origins of sarcopenia. J Nutr Health Aging
. [Review]. 2008; 12 (7): 427–32.
35. Simpson RU, Thomas GA, Arnold AJ. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem
. 1985; 260 (15): 8882–91.
36. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care
. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Government Review]. 2008; 11 (6): 693–700.
37. Stewart JW, Alekel DL, Ritland LM, Van Loan M, Gertz E, Genschel U. Serum 25-hydroxyvitamin D is related to indicators of overall physical fitness in healthy postmenopausal women. Menopause
. 2009; 16 (6): 1093–101.
38. Taylor HL, Jacobs DR Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis
. 1978; 31 (12): 741–55.
39. Van Kan GA, Cderbaum JM, Cesari M, et al.. Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research). J Nutr Health Aging
. 2011; 15 (10): 834–46.
40. Villalon KL, Gozansky WS, Van Pelt RE, et al.. A losing battle: weight regain does not restore weight loss-induced bone loss in postmenopausal women. Obesity
. [Research Support, N.I.H., Extramural]. 2011; 19 (12): 2345–50.
41. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle
. 2010; 1 (2): 129–33.
CALORIC RESTRICTION; WEIGHT LOSS; 25-HYDROXYVITAMIN D; AGING
©2013The American College of Sports Medicine
Highlight selected keywords in the article text.